1. Home
  2. ERAS vs OOMA Comparison

ERAS vs OOMA Comparison

Compare ERAS & OOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ERAS
  • OOMA
  • Stock Information
  • Founded
  • ERAS 2018
  • OOMA 2003
  • Country
  • ERAS United States
  • OOMA United States
  • Employees
  • ERAS N/A
  • OOMA N/A
  • Industry
  • ERAS Biotechnology: Pharmaceutical Preparations
  • OOMA EDP Services
  • Sector
  • ERAS Health Care
  • OOMA Technology
  • Exchange
  • ERAS Nasdaq
  • OOMA Nasdaq
  • Market Cap
  • ERAS 348.4M
  • OOMA 379.7M
  • IPO Year
  • ERAS 2021
  • OOMA 2015
  • Fundamental
  • Price
  • ERAS $1.45
  • OOMA $12.08
  • Analyst Decision
  • ERAS Strong Buy
  • OOMA Buy
  • Analyst Count
  • ERAS 6
  • OOMA 6
  • Target Price
  • ERAS $4.83
  • OOMA $17.63
  • AVG Volume (30 Days)
  • ERAS 1.2M
  • OOMA 190.1K
  • Earning Date
  • ERAS 08-11-2025
  • OOMA 08-26-2025
  • Dividend Yield
  • ERAS N/A
  • OOMA N/A
  • EPS Growth
  • ERAS N/A
  • OOMA N/A
  • EPS
  • ERAS N/A
  • OOMA N/A
  • Revenue
  • ERAS N/A
  • OOMA $259,382,000.00
  • Revenue This Year
  • ERAS N/A
  • OOMA $6.38
  • Revenue Next Year
  • ERAS N/A
  • OOMA $6.45
  • P/E Ratio
  • ERAS N/A
  • OOMA N/A
  • Revenue Growth
  • ERAS N/A
  • OOMA 7.01
  • 52 Week Low
  • ERAS $1.01
  • OOMA $7.83
  • 52 Week High
  • ERAS $3.45
  • OOMA $17.00
  • Technical
  • Relative Strength Index (RSI)
  • ERAS 52.19
  • OOMA 37.45
  • Support Level
  • ERAS $1.38
  • OOMA $13.00
  • Resistance Level
  • ERAS $1.58
  • OOMA $13.30
  • Average True Range (ATR)
  • ERAS 0.11
  • OOMA 0.35
  • MACD
  • ERAS 0.01
  • OOMA -0.02
  • Stochastic Oscillator
  • ERAS 64.86
  • OOMA 12.24

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

About OOMA Ooma Inc.

Ooma Inc is a communications services company. It is a smart software-as-a-service ("SaaS") and unified communications platform that deliver voice and collaboration features including messaging, intelligent virtual attendants and video conferencing, and residential phone service provides PureVoice high-definition voice quality, advanced functionality and integration with mobile devices. Its services rely upon the following main elements: multi-tenant cloud service, on-premise devices, desktop and mobile applications, and calling platforms. Ooma generates revenues from the sale of subscriptions and other services.

Share on Social Networks: